Back

Risk modifiers and mortality in patients with high platelet reactivity to Adenosine-diphosphate (ADP) in the LURIC study

30 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Atrial Fibrillation, Platelet Aggregation and Outcomes Biomarkers ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Martin Berger

RWTH University Hospital Aachen, Aachen (Germany)

6 More presentations in this session

Presentation thumbnail
Impact of body mass index on outcomes in european patients with atrial fibrillation: the ESC EHRA EORP Atrial Fibrillation General Long-Term Registry (AFGen LT)
Professor G. Boriani (Modena, IT)
Abstract Slides
Presentation thumbnail
Atrial fibrillation risk factor burden and disease onset across age decades.
Associate Professor B. Morseth (Tromso, NO)
Abstract Slides
Presentation thumbnail
Clinical phenotypes of atrial fibrillation and risk of mortality: a cluster analysis.
Assistant Professor D. Pastori (Rome, IT)
Abstract Slides
Presentation thumbnail
Long term antithrombotic treatment in atrial fibrillation patients undergoing coronary surgery.
Doctor M. Skibniewski (Linkoping, SE)
Abstract Slides
Presentation thumbnail
Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial
Associate Professor B. Rocca (Casamassima, IT)
Abstract Slides

Access the full session

Session thumbnail
Atrial Fibrillation, Platelet Aggregation and Outcomes

The Event

Event poster

ESC Congress 2020

30 August 2020 08:30 CET
You may be interested in
thumbnail
Webinar
Biomarkers of clinical utility in cardiovascular disease
thumbnail
Congress Session
Challenges and innovations in cardiovascular risk stratification with cardiac biomarkers
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources